New and converging technology continue to push the bounds of what is patentable. Business method patents may be patent-eligible, but what separates a patentable method from a mere abstract idea or phenomenon of nature? How has Bilski and its progeny impacted your patent procurement and enforcement strategy? This panel will examine the debate between having a competitive advantage vs. the greater good and how the following issues are affecting your business:
- Did the Supreme Court provide sufficient guidance to lower courts on the appropriate test for patent-eligibility? Is the “machine or transformation” test appropriate for all technologies?
- The impact of Bilski on procurement and enforcement strategies:
- How to draft patent claims most likely to survive a § 101 challenge
- How the Supreme Court’s decision will impact litigation tactics
- How to draft patent claims most likely to survive a § 101 challenge
- The repercussions for innovation
- Revised approaches for protecting proprietary methods
Panelists:
- Paul Hunter, Vice Chair, Electronics Practice
- Steve Rizzi, Chair, China Practice
- James Smith, Associate GC & Chief IP Officer, Baxter Healthcare Corporation
- E. Earle Thompson, Chief Intellectual Property Counsel, SanDisk Corporation
- Mialeeka Williams, Counsel, The Coca-Cola Company
- Michael Whitehead, Chief Counsel, Intellectual Property, The Lincoln Electric Company
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.